RemeGen Schedules 28 April 2026 Board Meeting to Review Q1 2026 Unaudited Results

Bulletin Express

04/16

RemeGen Co., Ltd. announced that its board of directors will convene on 28 April 2026 to consider and approve the unaudited financial results for the three months ended 31 March 2026, along with the related public disclosure.

The meeting will be chaired by Mr. Wang Weidong, who serves as chairman and executive director. The current board comprises four executive directors (Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Wen Qingkai, Mr. Lin Jian), two non-executive directors (Dr. Wang Liqiang, Dr. Su Xiaodi), and three independent non-executive directors (Mr. Hao Xianjing, Mr. Chen Yunjin, Mr. Huang Guobin).

The company is incorporated in the People’s Republic of China and remains committed to timely dissemination of its financial performance. Details of the unaudited first-quarter results will be published following board approval.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1174576271"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1174576271\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1174576271?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-16 17:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174576271","market":"hk","top_or_hot":-1,"title":"RemeGen Schedules 28 April 2026 Board Meeting to Review Q1 2026 Unaudited Results","media":"Bulletin Express","content":"<p>RemeGen Co., Ltd. announced that its board of directors will convene on 28 April 2026 to consider and approve the unaudited financial results for the three months ended 31 March 2026, along with the related public disclosure.</p>\n<p>The meeting will be chaired by Mr. Wang Weidong, who serves as chairman and executive director. The current board comprises four executive directors (Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Wen Qingkai, Mr. Lin Jian), two non-executive directors (Dr. Wang Liqiang, Dr. Su Xiaodi), and three independent non-executive directors (Mr. Hao Xianjing, Mr. Chen Yunjin, Mr. Huang Guobin).</p>\n<p>The company is incorporated in the People’s Republic of China and remains committed to timely dissemination of its financial performance. Details of the unaudited first-quarter results will be published following board approval.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RemeGen Schedules 28 April 2026 Board Meeting to Review Q1 2026 Unaudited Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRemeGen Schedules 28 April 2026 Board Meeting to Review Q1 2026 Unaudited Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-16 17:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>RemeGen Co., Ltd. announced that its board of directors will convene on 28 April 2026 to consider and approve the unaudited financial results for the three months ended 31 March 2026, along with the related public disclosure.</p>\n<p>The meeting will be chaired by Mr. Wang Weidong, who serves as chairman and executive director. The current board comprises four executive directors (Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Wen Qingkai, Mr. Lin Jian), two non-executive directors (Dr. Wang Liqiang, Dr. Su Xiaodi), and three independent non-executive directors (Mr. Hao Xianjing, Mr. Chen Yunjin, Mr. Huang Guobin).</p>\n<p>The company is incorporated in the People’s Republic of China and remains committed to timely dissemination of its financial performance. Details of the unaudited first-quarter results will be published following board approval.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1174576271","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174576271","pubTimestamp":1776330231,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"RemeGen Co., Ltd. announced that its board of directors will convene on 28 April 2026 to consider and approve the unaudited financial results for the three months ended 31 March 2026, along with the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"RemeGen计划于2026年4月28日召开董事会，审查2026年第一季度未经审计的业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"RemeGen Co., Ltd. announced that its board of directors will convene on 28 April 2026 to consider and approve the unaudited financial results for the three months ended 31 March 2026, along with the related public disclosure.\nThe meeting will be chaired by Mr. Wang Weidong, who serves as chairman and executive director. The current board comprises four executive directors (Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Wen Qingkai, Mr. Lin Jian), two non-executive directors (Dr. Wang Liqiang, Dr. Su Xiaodi), and three independent non-executive directors (Mr. Hao Xianjing, Mr. Chen Yunjin, Mr. Huang Guobin).\nThe company is incorporated in the People’s Republic of China and remains committed to timely dissemination of its financial performance. Details of the unaudited first-quarter results will be published following board approval.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}